A few interesting articles. Pending trial results, looks like we've got some very hot property.
https://www.fiercepharma.com/pharma/pleasant-surprise-gsk-fda-approves-jak-drug-momelotinib-broader-blood-cancer-use
The $1.9 billion acquisition of momelotinib was based on second-line treatment
"When GSK purchased Ojjaara’s developer Sierra last year, the company valued the biotech based on a potential second-line approval"
"Moving forward, GSK is exploring potential combinations, including with a BET inhibitor, Miels said. Without giving out more details, the commercial chief said GSK is also interested in other hematological indications such as myelodysplastic syndromes, where anemia is also problem."
https://www.fiercebiotech.com/biotech/novartis-may-have-bought-morphosys-it-only-had-eyes-its-bet-inhibitor
Novartis picked up Morphosys in bidding war, only wanted pelabresib but bought the whole company.
https://www.fiercepharma.com/pharma/competitor-rollouts-and-patent-cliff-incyte-banks-jakafi-resilience-new-disease-and
Jakafi patents expiring in 2028.
